- Home
- SWIM vs EXAI Comparison
SWIM vs EXAI Comparison
Compare SWIM & EXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIM
- EXAI
- Stock Information
- Founded
- SWIM 1956
- EXAI 2012
- Country
- SWIM United States
- EXAI United Kingdom
- Employees
- SWIM N/A
- EXAI 483
- Industry
- SWIM Plastic Products
- EXAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SWIM Industrials
- EXAI Health Care
- Exchange
- SWIM Nasdaq
- EXAI Nasdaq
- Market Cap
- SWIM 751.3M
- EXAI 613.6M
- IPO Year
- SWIM 2021
- EXAI 2021
- Fundamental
- Price
- SWIM $5.72
- EXAI $4.69
- Analyst Decision
- SWIM Hold
- EXAI Hold
- Analyst Count
- SWIM 5
- EXAI 4
- Target Price
- SWIM $5.62
- EXAI $7.00
- AVG Volume (30 Days)
- SWIM 695.0K
- EXAI 702.2K
- Earning Date
- SWIM 11-05-2024
- EXAI 11-26-2024
- Dividend Yield
- SWIM N/A
- EXAI N/A
- EPS Growth
- SWIM N/A
- EXAI N/A
- EPS
- SWIM 0.10
- EXAI N/A
- Revenue
- SWIM $512,114,000.00
- EXAI $22,877,630.00
- Revenue This Year
- SWIM N/A
- EXAI $156.33
- Revenue Next Year
- SWIM $5.14
- EXAI N/A
- P/E Ratio
- SWIM $57.51
- EXAI N/A
- Revenue Growth
- SWIM N/A
- EXAI N/A
- 52 Week Low
- SWIM $2.11
- EXAI $3.80
- 52 Week High
- SWIM $7.33
- EXAI $7.91
- Technical
- Relative Strength Index (RSI)
- SWIM 39.61
- EXAI 40.59
- Support Level
- SWIM $5.40
- EXAI $4.80
- Resistance Level
- SWIM $6.16
- EXAI $6.15
- Average True Range (ATR)
- SWIM 0.34
- EXAI 0.38
- MACD
- SWIM -0.09
- EXAI -0.01
- Stochastic Oscillator
- SWIM 24.32
- EXAI 0.00
About SWIM Latham Group Inc.
Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. It derives a majority of its revenue from the United States.
About EXAI Exscientia Plc
Exscientia PLC is engaged in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of novel therapeutic compounds. The company's technology platform combines human and computational capabilities to accelerate the process of designing novel, safe, and efficacious compounds for clinical testing in humans. The company is focused on the discovery and development of small-molecule drug candidates.